



Media Contact  
Dan McFadden  
[dmcfadden@oculusis.com](mailto:dmcfadden@oculusis.com)  
(425) 836-3103

## **MEXICO'S MINISTRY OF HEALTH TO INITIATE LIMITED CLINICAL TRIALS OF OCULUS'S "L3" ONCOLOGY COMPOUND IN TREATMENT OF CERVICAL CANCER**

**Proprietary oncology compound shown to be an inhibitor of cell growth in a wide range of cancer cell types including cervical cancer.**

**PETALUMA, CA (August 28, 2003)**— Thirty days after securing approval for the distribution of Microcyn 60 disinfectant and antiseptic in Mexico, Hoji Alimi, CEO and founder of Oculus Innovative Sciences ([www.oculusis.com](http://www.oculusis.com)), today announced that the Mexican Ministry of Health has recorded positive laboratory results and intends to initiate limited human clinical trials of Oculus's proprietary oncology compound, code named "L3." The trials, to begin in early 2004, will focus on the application of L3 in the treatment of cervical cancer, a major health issue in Mexico and other Latin American countries.

Third-party in vitro research along with FDA-recommended animal studies have demonstrated that the L3 compound inhibits the growth of a wide range and types of cancers. Based on test results to date, the company believes the L3 compound will produce safe and effective results in the treatment of cancers in humans. In light of L3's non-toxic nature, patients treated with the compound are not anticipated to experience the serious adverse reactions common to most chemotherapy agents. L3 can be potentially used on lesions post-removal of tumors where, oftentimes, cells are left behind that may later metastasize. This treatment may result in inhibiting the growth of residual cancer cells. The L3 compound can be applied locally through injection or spray.

Worldwide, cervical cancer kills nearly 500,000 women annually. Cervical cancer screening, which can detect precancerous and cancer changes early, is not readily employed in countries outside of the United States. According to the American Cancer Society, in the U.S. alone, an estimated 12,200 cases of cervical cancer are expected to be diagnosed in 2003, with 4,100 of those women dying.

L3's mode of action is to attach to the cell membrane receptor, which may deactivate the G-protein cascade ultimately resulting in cell division. In laboratory testing using mice, tumors treated with L3 failed to grow. The binding of L3 to a cell appears to be immediate and permanent, providing a

significant advantage since the patient would not require repeated treatments for inhibition of tumor growth. L3, however, will not yet be able to treat blood-related cancers since the compound will readily react with any protein.

“We are pleased with the progress made to date on L3 and equally important, with the excellent response regarding L3 received from the outstanding physicians and health care professionals in Mexico on this exciting life-saving technology,” said Mr. Alimi.

### **About Oculus**

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative services and technologies that can improve patient health worldwide. The company has at its foundation two wholly owned subsidiaries, MicroMed Consulting Services and AquaMed Technologies. Oculus has overseen the evolution of the Microcyn 60 disinfectant from technology to product as well as the development of an anti-cancer drug (L3) that shows promise in the prevention of many aggressive cancers including cervical cancer and melanomas. This same L3 compound has great potential in other applications based on its cell growth inhibition characteristics such as the drug-eluting stent products reducing restenosis. For more information, please visit us at [www.oculusis.com](http://www.oculusis.com).

### **Forward-Looking Statements**

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.